Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01649167 |
| Other study ID # |
MACSSD042010 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
July 17, 2012 |
| Last updated |
July 24, 2012 |
| Start date |
February 2009 |
| Est. completion date |
November 2010 |
Study information
| Verified date |
July 2012 |
| Source |
Materno-Perinatal Hospital of the State of Mexico |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Mexico: Secretaria de Salud |
| Study type |
Observational
|
Clinical Trial Summary
Background: Obesity in pregnancy is increasing and is a risk factor for metabolic pathology
such as preeclampsia. Leptin is an adipokine which has a direct relationship to obesity.
Aim: to measure leptin in lean, obese and diabetic pregnant women at three months intervals
throughout their pregnancies.
Methods: Pregnant women were recruited in the 1st trimester of pregnancy, and three groups
were formed: a) with pregestational Body Mass Index (BMI) less than 25 kg/m2, b) BMI higher
than 25 kg/m2 and c) with Gestational Diabetes Mellitus (GDM). Serum levels of leptin were
measured with radioimmunoassay (RIA) technique.
Description:
1. Introduction Obesity and type 2 diabetes (2DM) are worldwide health issues, and the
incidences of both diseases are increasing rapidly. Recent research has shown that maternal
nutrition during pregnancy may have long-term metabolic consequences in offspring. Many
pregnant women are obese (body mass index (BMI) > 30 kg/m2). The prevalence of maternal
obesity is rising, up to 20% in some antenatal clinics, which is in line with the prevalence
of obesity in the general population. Obesity in pregnancy has been linked to several
adverse pregnancy outcomes, including spontaneous abortion, preeclampsia, gestational
diabetes (GDM), fetal macrosomia, cesarean delivery, and wound complications post-cesarean
section. Both intrapartum and postpartum management of obese gravidas require
multidisciplinary consultations between obstetricians, anesthesiologists, nurses, and
pediatricians in order to improve the pregnancy outcomes of the mother and neonate. The
American College of Obstetricians and Gynecologists (ACOG) and several authors currently
support risk-reducing strategies for obese pregnant patients including limiting weight gain.
Preeclampsia is a multisystem disorder characterized by pregnancy-induced or gestational
hypertension and new-onset proteinuria during the second half of pregnancy.
The aim of this study was to measure leptin in lean, obese and diabetic pregnant women at
three-month intervals throughout their pregnancies to determine if this hormone could serve
as a prognostic marker for preeclampsia risk.
Recruitment Women were recruited at their first visit at 10-15 weeks gestation. They were
asked to attend after an overnight fast and were tested between 0700 and 0900 h. Three
groups of pregnant women were formed: a) normal weight (pregestational (PG) BMI < 25 kg/m2),
b) overweight-obese (PGBMI ≥ 25 kg/m2) and c) hyperglycemic in the first trimester of
pregnancy confirmed as GDM in women previously known to be normoglycemic. Positive cases for
preeclampsia were then subdivided.
Clinical follow-up Three examinations were performed in the 1st, 2nd, and 3rd trimesters. In
each visit, the women were weighed. Blood pressure (BP) was recorded at each visit using a
standard sphygmomanometer and appropriately sized cuff. If diagnosed with pregnancy-induced
hypertension, the women were hospitalized and clinically supervised with an electronic
monitor (Mercury, Mennem Medical) until the diagnosis of preeclampsia was confirmed or
excluded.
Laboratory During each consult, blood samples were collected in Vacutainer tubes after a
fasting period of 8 hours and centrifuged to separate the plasma from serum. The
investigators measured albumin (mg/dl), cholesterol (mg/dl), creatinine (mg/dl), glucose
(mg/dl), triglycerides (mg/dl), uric acid (mg/dl), liver enzymes (Dimension Rx L Max, Dade
Behring), and hemoglobin (g/dl) (Advia 120, Bayer Health) and performed a general urine test
(URiSCAN Pro). These tests were measured in the HMPMP according to standardized procedures
recommended by the International Federation of Clinical Chemistry and Laboratory Medicine
(IFCC).
Diagnosis of GDM At the time of recruitment, women with hyperglycemia who fulfilled the
criteria and were recently diagnosed with diabetes were included in the same group as those
women who were submitted to an OGT after 24 weeks' gestation and confirmed to have GDM
because they had normal values of glucose prior to their pregnancies.
During pregnancy follow-up, gynecologists at the obstetric outpatient clinic used the
following risk factors to screen women for GDM: a first-degree relative with diabetes, a
history of GDM or macrosomia, a suspicion of macrosomia in the current pregnancy, persistent
glucosuria, a rapid or excessive weight gain during early pregnancy, obesity or a random
plasma glucose ≥ 7.0 mmol/l. Women with one or more of these factors underwent the standard
100 g 3-h OGTT after an overnight fast (solution provided by Laboratorio Silanes).
The diagnosis of GDM was made according to the National Diabetes Data Group (NDDG) criteria
(≥ 2 abnormal values; glucose concentrations of ≥ 5.8 mmol/l for fasting, ≥ 10.6 mmol/l at 1
h, ≥ 9.2 mmol/l at 2 h, and ≥ 8.1 mmol/l at 3 h) [16].
In women with GDM, the therapeutic aims were blood glucose levels before meals < 5.0 mmol/l
and 2 h postprandial < 6.5 mmol/l. If two blood glucose levels in one to two weeks were
above these aims despite adequate dietary measures, then insulin of the rapid type was
started or doses were increased. If these measures were insufficient to reach the
therapeutic aims, then basal insulin was added.
Preeclampsia was diagnosed and classified according to the criteria specified by the
technical bulletin of the ACOG and the National High Blood Pressure Education Program
(NHBPEP) Working Group Report on High Blood Pressure in Pregnancy. Hypertension was
described as an increase of 30 mm Hg systolic or 15 mm Hg diastolic BP as compared to the
values before 20 weeks of pregnancy, or an absolute BP > 140/90 mm Hg after 20 weeks
gestation if the earlier values were unknown.
Leptin Serum levels of leptin (Millipore/Linco., USA, Cat. HL-8IHK) and adiponectin
(Millipore/Linco., USA, Cat. No. HADP-61HK) were determined by means of a double antibody
radioimmunoassay (RIA) using materials and protocols supplied by the provider
(Millipore/Linco., USA, Cat. HL-8IHK). All samples of each trimester were assayed
simultaneously. The assays were run according to the manufacturer's recommendations.
Statistical analysis It was used the SPSS version 16. Continuous variables were expressed in
means ± standard deviation (SD). Kruskal Wallis and Mann-Whitney U tests were considered
statistically significant with a P value ≤ 0.05. Receiver Operating Characteristic (ROC)
curves were used with each variable and in the cases of preeclampsia.
